19 results on '"Oertel, Bruno Georg"'
Search Results
2. Necessity and Risks of Arterial Blood Sampling in Healthy Volunteer Studies
- Author
-
Oertel, Bruno Georg, Vermehren, Johannes, Zimmermann, Michael, Huynh, Thomas Tao, Doehring, Alexandra, Ferreiros, Nerea, Senzel, Stephan, Schmitz-Rixen, Thomas, Erbe, Matthias, Geisslinger, Gerd, Harder, Sebastian, Angst, Martin S., and Lötsch, Jörn
- Published
- 2012
- Full Text
- View/download PDF
3. Central encoding of the strength of intranasal chemosensory trigeminal stimuli in a human experimental pain setting
- Author
-
Lötsch, Jörn, Oertel, Bruno Georg, Felden, Lisa, Nöth, Ulrike, Deichmann, Ralf, Hummel, Thomas, Walter, Carmen, Lötsch, Jörn, Oertel, Bruno Georg, Felden, Lisa, Nöth, Ulrike, Deichmann, Ralf, Hummel, Thomas, and Walter, Carmen
- Abstract
An important measure in pain research is the intensity of nociceptive stimuli and their cortical representation. However, there is evidence of different cerebral representations of nociceptive stimuli, including the fact that cortical areas recruited during processing of intranasal nociceptive chemical stimuli included those outside the traditional trigeminal areas. Therefore, the aim of this study was to investigate the major cerebral representations of stimulus intensity associated with intranasal chemical trigeminal stimulation. Trigeminal stimulation was achieved with carbon dioxide presented to the nasal mucosa. Using a single‐blinded, randomized crossover design, 24 subjects received nociceptive stimuli with two different stimulation paradigms, depending on the just noticeable differences in the stimulus strengths applied. Stimulus‐related brain activations were recorded using functional magnetic resonance imaging with event‐related design. Brain activations increased significantly with increasing stimulus intensity, with the largest cluster at the right Rolandic operculum and a global maximum in a smaller cluster at the left lower frontal orbital lobe. Region of interest analyses additionally supported an activation pattern correlated with the stimulus intensity at the piriform cortex as an area of special interest with the trigeminal input. The results support the piriform cortex, in addition to the secondary somatosensory cortex, as a major area of interest for stimulus strength‐related brain activation in pain models using trigeminal stimuli. This makes both areas a primary objective to be observed in human experimental pain settings where trigeminal input is used to study effects of analgesics.
- Published
- 2020
4. Machine-learned association of next-generation sequencing-derived variants in thermosensitive ion channels genes with human thermal pain sensitivity phenotypes
- Author
-
Lötsch, Jörn, Kringel, Dario, Geisslinger, Gerd, Oertel, Bruno Georg, Resch, Eduard, Malkusch, Sebastian, Lötsch, Jörn, Kringel, Dario, Geisslinger, Gerd, Oertel, Bruno Georg, Resch, Eduard, and Malkusch, Sebastian
- Abstract
Genetic association studies have shown their usefulness in assessing the role of ion channels in human thermal pain perception. We used machine learning to construct a complex phenotype from pain thresholds to thermal stimuli and associate it with the genetic information derived from the next-generation sequencing (NGS) of 15 ion channel genes which are involved in thermal perception, including ASIC1, ASIC2, ASIC3, ASIC4, TRPA1, TRPC1, TRPM2, TRPM3, TRPM4, TRPM5, TRPM8, TRPV1, TRPV2, TRPV3, and TRPV4. Phenotypic information was complete in 82 subjects and NGS genotypes were available in 67 subjects. A network of artificial neurons, implemented as emergent self-organizing maps, discovered two clusters characterized by high or low pain thresholds for heat and cold pain. A total of 1071 variants were discovered in the 15 ion channel genes. After feature selection, 80 genetic variants were retained for an association analysis based on machine learning. The measured performance of machine learning-mediated phenotype assignment based on this genetic information resulted in an area under the receiver operating characteristic curve of 77.2%, justifying a phenotype classification based on the genetic information. A further item categorization finally resulted in 38 genetic variants that contributed most to the phenotype assignment. Most of them (10) belonged to the TRPV3 gene, followed by TRPM3 (6). Therefore, the analysis successfully identified the particular importance of TRPV3 and TRPM3 for an average pain phenotype defined by the sensitivity to moderate thermal stimuli.
- Published
- 2020
5. Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research
- Author
-
Oertel, Bruno Georg and Lötsch, Jörn
- Published
- 2013
- Full Text
- View/download PDF
6. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action
- Author
-
Lötsch, Jörn, Skarke, Carsten, Wieting, Johannes, Oertel, Bruno Georg, Schmidt, Helmut, Brockmöller, Jürgen, and Geisslinger, Gerd
- Published
- 2006
7. A data science approach to the selection of most informative readouts of the human intradermal capsaicin pain model to assess pregabalin effects
- Author
-
Lötsch, Jörn, Walter, Carmen, Zunftmeister, Martin, Zinn, Sebastian, Wolters, Miriam, Ferreirós Bouzas, Nerea, Rossmanith, Tanja, Oertel, Bruno Georg, Geisslinger, Gerd, Lötsch, Jörn, Walter, Carmen, Zunftmeister, Martin, Zinn, Sebastian, Wolters, Miriam, Ferreirós Bouzas, Nerea, Rossmanith, Tanja, Oertel, Bruno Georg, and Geisslinger, Gerd
- Abstract
Persistent and, in particular, neuropathic pain is a major healthcare problem with still insufficient pharmacological treatment options. This triggered research activities aimed at finding analgesics with a novel mechanism of action. Results of these efforts will need to pass through the phases of drug development, in which experimental human pain models are established components e.g. implemented as chemical hyperalgesia induced by capsaicin. We aimed at ranking the various readouts of a human capsaicin–based pain model with respect to the most relevant information about the effects of a potential reference analgesic. In a placebo‐controlled, randomized cross‐over study, seven different pain‐related readouts were acquired in 16 healthy individuals before and after oral administration of 300 mg pregabalin. The sizes of the effect on pain induced by intradermal injection of capsaicin were quantified by calculating Cohen's d. While in four of the seven pain‐related parameters, pregabalin provided a small effect judged by values of Cohen's d exceeding 0.2, an item categorization technique implemented as computed ABC analysis identified the pain intensities in the area of secondary hyperalgesia and of allodynia as the most suitable parameters to quantify the analgesic effects of pregabalin. Results of this study provide further support for the ability of the intradermal capsaicin pain model to show analgesic effects of pregabalin. Results can serve as a basis for the designs of studies where the inclusion of this particular pain model and pregabalin is planned.
- Published
- 2019
8. Quantitative sensory testing response patterns to capsaicin- and ultraviolet-B-induced local skin hypersensitization in healthy subjects : a machine-learned analysis
- Author
-
Lötsch, Jörn, Geisslinger, Gerd, Heinemann, Sarah, Lerch, Florian, Oertel, Bruno Georg, Ultsch, Alfred, Lötsch, Jörn, Geisslinger, Gerd, Heinemann, Sarah, Lerch, Florian, Oertel, Bruno Georg, and Ultsch, Alfred
- Abstract
The comprehensive assessment of pain-related human phenotypes requires combinations of nociceptive measures that produce complex high-dimensional data, posing challenges to bioinformatic analysis. In this study, we assessed established experimental models of heat hyperalgesia of the skin, consisting of local ultraviolet-B (UV-B) irradiation or capsaicin application, in 82 healthy subjects using a variety of noxious stimuli. We extended the original heat stimulation by applying cold and mechanical stimuli and assessing the hypersensitization effects with a clinically established quantitative sensory testing (QST) battery (German Research Network on Neuropathic Pain). This study provided a 246 × 10-sized data matrix (82 subjects assessed at baseline, following UV-B application, and following capsaicin application) with respect to 10 QST parameters, which we analyzed using machine-learning techniques. We observed statistically significant effects of the hypersensitization treatments in 9 different QST parameters. Supervised machine-learned analysis implemented as random forests followed by ABC analysis pointed to heat pain thresholds as the most relevantly affected QST parameter. However, decision tree analysis indicated that UV-B additionally modulated sensitivity to cold. Unsupervised machine-learning techniques, implemented as emergent self-organizing maps, hinted at subgroups responding to topical application of capsaicin. The distinction among subgroups was based on sensitivity to pressure pain, which could be attributed to sex differences, with women being more sensitive than men. Thus, while UV-B and capsaicin share a major component of heat pain sensitization, they differ in their effects on QST parameter patterns in healthy subjects, suggesting a lack of redundancy between these models.
- Published
- 2017
9. Multimodal distribution of human cold pain thresholds
- Author
-
Lötsch, Jörn, Dimova, Violeta, Lieb, Isabel, Zimmermann, Michael, Oertel, Bruno Georg, Ultsch, Alfred, Lötsch, Jörn, Dimova, Violeta, Lieb, Isabel, Zimmermann, Michael, Oertel, Bruno Georg, and Ultsch, Alfred
- Abstract
Background: It is assumed that different pain phenotypes are based on varying molecular pathomechanisms. Distinct ion channels seem to be associated with the perception of cold pain, in particular TRPM8 and TRPA1 have been highlighted previously. The present study analyzed the distribution of cold pain thresholds with focus at describing the multimodality based on the hypothesis that it reflects a contribution of distinct ion channels. Methods: Cold pain thresholds (CPT) were available from 329 healthy volunteers (aged 18 - 37 years; 159 men) enrolled in previous studies. The distribution of the pooled and log-transformed threshold data was described using a kernel density estimation (Pareto Density Estimation (PDE)) and subsequently, the log data was modeled as a mixture of Gaussian distributions using the expectation maximization (EM) algorithm to optimize the fit. Results: CPTs were clearly multi-modally distributed. Fitting a Gaussian Mixture Model (GMM) to the log-transformed threshold data revealed that the best fit is obtained when applying a three-model distribution pattern. The modes of the identified three Gaussian distributions, retransformed from the log domain to the mean stimulation temperatures at which the subjects had indicated pain thresholds, were obtained at 23.7 °C, 13.2 °C and 1.5 °C for Gaussian #1, #2 and #3, respectively. Conclusions: The localization of the first and second Gaussians was interpreted as reflecting the contribution of two different cold sensors. From the calculated localization of the modes of the first two Gaussians, the hypothesis of an involvement of TRPM8, sensing temperatures from 25 - 24 °C, and TRPA1, sensing cold from 17 °C can be derived. In that case, subjects belonging to either Gaussian would possess a dominance of the one or the other receptor at the skin area where the cold stimuli had been applied. The findings therefore support a suitability of complex analytical approaches to detect mechanistically determined
- Published
- 2015
10. Inverted perceptual judgment of nociceptive stimuli at threshold level following inconsistent cues
- Author
-
Walter, Carmen, Dimova, Violeta, Bu, Julia, Parnham, Michael J., Oertel, Bruno Georg, Lötsch, Jörn, Walter, Carmen, Dimova, Violeta, Bu, Julia, Parnham, Michael J., Oertel, Bruno Georg, and Lötsch, Jörn
- Abstract
Objective: The perception of pain is susceptible to modulation by psychological and contextual factors. It has been shown that subjects judge noxious stimuli as more painful in a respective suggestive context, which disappears when the modifying context is resolved. However, a context in which subjects judge the painfulness of a nociceptive stimulus in exactly the opposite direction to that of the cues has never been shown so far. Methods: Nociceptive stimuli (300 ms intranasal gaseous CO2) at the individual pain threshold level were applied after a visual cue announcing the stimulus as either "no pain", merely a "stimulus", or "pain". Among the stimuli at threshold level, other CO2 stimuli that were clearly below or above pain threshold were randomly interspersed. These were announced beforehand in 12 subjects randomly with correct or incorrect cues, i.e., clearly painful or clearly non-painful stimuli were announced equally often as not painful or painful. By contrast, in a subsequent group of another 12 subjects, the stimuli were always announced correctly with respect to the evoked pain. Results: The random and often incorrect announcement of stimuli clearly below or above pain threshold caused the subjects to rate the stimuli at pain-threshold level in the opposite direction of the cue, i.e., when the stimuli were announced as "pain" significantly more often than as non-painful and vice versa (p < 10-4). By contrast, in the absence of incongruence between announcement and perception of the far-from-threshold stimuli, stimuli at pain threshold were rated in the cued direction. Conclusions: The present study revealed the induction of associations incongruent with a given message in the perception of pain. We created a context of unreliable cues whereby subjects perceived the stimulus opposite to that suggested by a prior cue, i.e., potentially nociceptive stimuli at pain threshold level that were announced as painful were judged as non-painful and vice versa. The
- Published
- 2015
11. Lack of fluconazole effects on human chemosensation
- Author
-
Oertel, Bruno Georg, primary, Huynh, Thomas Tao, additional, Hummel, Thomas, additional, and Lötsch, Jörn, additional
- Published
- 2015
- Full Text
- View/download PDF
12. Consequences of a human TRPA1 genetic variant on the perception of nociceptive and olfactory stimuli
- Author
-
Schütz, Michael, Oertel, Bruno Georg, Heimann, Dirk, Doehring, Alexandra, Walter, Carmen, Dimova, Violeta, Geisslinger, Gerd, Lötsch, Jörn, Schütz, Michael, Oertel, Bruno Georg, Heimann, Dirk, Doehring, Alexandra, Walter, Carmen, Dimova, Violeta, Geisslinger, Gerd, and Lötsch, Jörn
- Abstract
Background: TRPA1 ion channels are involved in nociception and are also excited by pungent odorous substances. Based on reported associations of TRPA1 genetics with increased sensitivity to thermal pain stimuli, we therefore hypothesized that this association also exists for increased olfactory sensitivity. Methods: Olfactory function and nociception was compared between carriers (n = 38) and non-carriers (n = 43) of TRPA1 variant rs11988795 G.A, a variant known to enhance cold pain perception. Olfactory function was quantified by assessing the odor threshold, odor discrimination and odor identification, and by applying 200-ms pulses of H2S intranasal. Nociception was assessed by measuring pain thresholds to experimental nociceptive stimuli (blunt pressure, electrical stimuli, cold and heat stimuli, and 200-ms intranasal pulses of CO2). Results: Among the 11 subjects with moderate hyposmia, carriers of the minor A allele (n = 2) were underrepresented (34 carriers among the 70 normosmic subjects; p = 0.049). Moreover, carriers of the A allele discriminated odors significantly better than non-carriers (13.161.5 versus 12.361.6 correct discriminations) and indicated a higher intensity of the H2S stimuli (29.2613.2 versus 21612.8 mm VAS, p = 0.006), which, however, could not be excluded to have involved a trigeminal component during stimulation. Finally, the increased sensitivity to thermal pain could be reproduced. Conclusions: The findings are in line with a previous association of a human TRPA1 variant with nociceptive parameters and extend the association to the perception of odorants. However, this addresses mainly those stimulants that involve a trigeminal component whereas a pure olfactory effect may remain disputable. Nevertheless, findings suggest that future TRPA1 modulating drugs may modify the perception of odorants.
- Published
- 2014
13. Der Mu-Opioidrezeptor-Polymorphismus 118A>G : ein genetischer Modulator von Opioideffekten
- Author
-
Oertel, Bruno Georg
- Subjects
Opiatrezeptor ,Analgesie ,ddc:610 ,Genetik - Abstract
The µ-opioid receptor is the primary target structure of most opioid analgesics and thus responsible for the predominant part of their wanted and unwanted effects. Carriers of the frequent genetic µ-opioid receptor variant N40D (allelic frequency 8.2 - 17 %), coded by the single nucleotide polymorphism A>G at position 118 of the µ-opioid receptor coding gene OPRM1 (OPRM1 118A>G SNP), suffer from a decreased opioid potency and from a higher need of opioid analgesics to reach adequate analgesia. The aim of the present work was to identify the mechanism by which the OPRM1 118A>G SNP decreases the opioid potency and to quantify its effects on the analgesic potency and therapeutic range of opioid analgesics. To elucidate the consequences of the OPRM1 118A>G SNP for the effects of opioid analgesics, brain regions of healthy homozygous carriers of the OPRM1 118A>G SNP were identified by means of functional magnetic resonace imaging (fMRI), where the variant alters the response to opioid analgesics after painful stimulation. Afterwards, the µ-opioid receptor function was analyzed on a molecular level in post mortem samples of these brain regions. Finally, the consequences of the OPRM1 118A>G SNP for the analgesic and respiratory depressive effects of opioids were quantified in healthy carriers and non-carriers of OPRM1 118A>G SNP by means of experimental pain- and respiratory depression-models. To identify pain processing brain regions, where the variant alters the response to opioid analgesics after painful stimulation, we investigated the effects of different alfentanil concentration levels (0, 25, 50 and 75 ng/ml) on pain-related brain activation achieved by short pulses (300 msec) of gaseous CO2 (66% v/v) delivered to the nasal mucosa using a 3.0 T magnetic head scanner in 16 non-carriers and nine homozygous carriers of the µ-opioid receptor gene variant OPRM1 118A>G. In brain regions associated with the processing of the sensory dimension of pain (pain intensity), such as the primary and secondary somatosensory cortices and the posterior insular cortex, the activation decreased linearly in relation to alfentanil concentrations, which was significantly less pronounced in OPRM1 118G carriers. In contrast, in brain regions known to process the affective dimension of pain (emotional dimension), such as the parahippocampal gyrus, amygdala and anterior insula, the pain-related activation disappeared already at the lowest alfentanil dose, without genotype differences. Subsequently, we investigated the µ-opioid receptor-expression ([3H]-DAMGO saturation experiments, OPRM1 mRNA analysis by means of RT-PCR), the µ-opioid receptor affinity ([3H]-DAMGO saturation and competition experiments) and µ-opioid receptor signaling ([35S]- GTPγS binding experiments) in post mortem samples of the human SII-region, as a cortical projection region coding for pain intensity, and lateral thalamus, as an important region for nociceptive transmission. Samples of 22 non-carriers, 21 heterozygous and three homozygous carriers of OPRM1 118A>G SNP were included into the analysis. The receptor expression and receptor affinity of both brain regions did not differ between non-carriers and carriers of the variant N40D. In non-carriers, the µ-opioid receptors of the SII-region activated the receptor bound G-protein more efficiently than those of the thalamus (factor 1.55-2.27). This regional difference was missing in heterozygous (factor 0.78-1.66) and homozygous (factor 0.66-1.15) carriers of the N40D variant indicating a reduced receptor-G-protein-coupling in the SII-region. Finally, the consequences of the alteration of µ-opioid receptor function in carriers and noncarriers of the genetic variant was investigated using pain- and respiratory depression-models. Therefore, 10 healthy non-carriers, four heterozygous and six homozygous carriers of the µ- opioid receptor variant N40D received an infusion of four different concentrations of alfentanil (0, 33.33, 66.66 and 100 ng/ml). At each concentration level, analgesia was assessed by means of electrically (5 Hz sinus 0 to 20 mA) and chemically (200 ms gaseous CO2 pulses applied to the nasal mucosa) induced pain, and respiratory depression was quantified by means of hypercapnic challenge according to Read and recording of the breathing frequency. The results showed that depending on the used pain model, both heterozygous and homozygous carriers of the variant N40D needed 2 – 4 times higher alfentanil concentrations to achieve the same analgesia as non-carriers. This increase seems to be at least for homozygous carriers unproblematic, because to reach a comparable respiratory depression as non-carriers, they needed 10-12 times higher alfentanil concentrations. The results of this work demonstrate that the µ-opioid receptor variant N40D causes a regionally limited reduction of the signal transduction efficiency of µ-opioid receptors in brain regions involved in pain processing. Thus, the painful activation of sensory brain regions coding for pain intensity is not sufficiently suppressed by opioid analgesics in carriers of the variant N40D. Due to the insufficient suppression in hetero- and homozygous carriers of the variant N40D, the concentration of opioids has to be increased by a factor 2 - 4, in order to achieve the same analgesia as in non-carriers. At the same time, the respiratory depressive effects are decreased to a greater extent in homozygous carriers of the N40D variant as they need a 10 - 12 times higher opioid concentration to suffer from the same degree of respiratory depression as non-carriers. Due to the increased therapeutic range of opioid analgesics, an increase of the opioid dose seems to be harmless, at least for homozygous carriers of the N40D variant. Opioidanalgetika sind bis heute das adäquate Mittel zur Behandlung schwerer Schmerzzustände. Dabei wird ihre breite Anwendbarkeit durch opioidtypische unerwünschte Nebenwirkungen wie Atemdepression, Benommenheit, Übelkeit bis zum Erbrechen, Obstipation, Miosis und juckende Hautreizung eingeschränkt. Das Ausmaß der auftretenden Opioidwirkungen variiert von Patient zu Patient. Fortschritte in der genetischen Forschung haben gezeigt, dass ein Teil der Variabilität von Opioidwirkungen in der genetischen Variabilität der Bevölkerung begründet liegt. Opioide wirken über G-Protein-gekoppelte Rezeptoren, die Opioidrezeptoren, bestehend aus dem μ-, κ-, δ-Opioidrezeptor. Anhand von μ-Opioidrezeptor-Knockout-Mäusen konnte gezeigt werden, dass vor allem die μ-Opioidrezeptoren für den überwiegenden Teil der erwünschten und unerwünschten Wirkungen von Opioidanalgetika verantwortlich sind. Die μ-Opioidrezeptoren werden vom OPRM1 Gen codiert. Bei einer häufigen genetischen Variante des μ- Opioidrezeptor-Gens OPRM1 (Allelfrequenz ca. 8,2-17%) steht an Position 118 in Exon 1 das Nukleotid Adenin anstatt Guanin (OPRM1-118A>G-Polymorphismus). Als Folge wird anstelle von Asparagin die Aminosäure Aspartat an Position 40 (N40D) der N-terminalen extrazellulä- ren Rezeptorbindungsdomäne eingebaut. Bei Trägern der μ-Opioidrezeptor-Variante N40D wurde wiederholt eine Verminderung der Opioidpotenz und ein erhöhter Bedarf von Opioidanalgetika zur adäquaten Schmerzstillung im Vergleich zu Nichtträgern der Variante beobachtet. Desweiteren weisen einige Studien auf eine Erhöhung der therapeutischen Breite von Opioidanalgetika in Trägern dieser Variante hin. So benötigten Träger der N40D Variante im Vergleich zu Nichtträgern höhere Konzentrationen von Alfentanil (1,3-fach) bzw. Morphin (2-fach), um die gleiche Analgesie bei postoperativen Schmerzen zu erreichen, und dennoch waren sie weniger von opioidtypischen unerwünschten Wirkungen betroffen. Die miotischen Effekte von Morphin, seines aktiven Metaboliten Morphin-6-glucuronid (M6G) und Levomethadon waren in Trägern der N40D Variante verringert und Träger des varianten Allels mussten nach hohen Dosen M6G weniger erbrechen als Nichtträger. Es gibt aber auch eine Studie, deren Ergebnisse gegen eine erhöhte therapeutische Breite von Opioiden in Träger des varianten 118G-Allels sprechen. Diese zeigte, dass in heterozygoten Trägern des 118G Allels die Analgesie nach M6G Gabe zwar verringert war, die atemdepressiven Effekte von M6G aber unverändert waren. Dies deutet auf eine verminderte therapeutische Breite von Opioiden in heterozygoten Trägern hin. Die der verminderten Opioidpotenz zu Grunde liegenden molekularen Mechanismen sind nicht eindeutig geklärt. So wurde in AV-12-Zellen, die mit der 118G Variante des µ-Opioidrezeptor-Gens transfiziert wurden, eine 3-fach höhere Affinität des N40D Rezeptors zu seinem endogenen Liganden β-Endorphin beobachtet, während die Affinität zu Opioiden wie Morphin oder dessen aktiven Metaboliten Morphin-6-glucuronid unverändert waren. Diese Ergebnisse erklären leider nicht die verminderte Opioidpotenz bei Trägern der 118G Variante. Eine mögliche Erklärung für die verminderte Opioidanalgesie wäre eine verminderte Rezeptorexpression in Trägern der 118G Variante. Die Möglichkeit einer verminderten Rezeptorexpression wird durch die Beobachtung gestützt, dass in Hirngewebsproben von Trägern der 118G Variante im Vergleich zu Nichtträgern tendenziell geringere Mengen an OPRM1 mRNA gefunden wurden, was auf eine verminderte Expression des Rezeptorproteins hinweisen könnte. Diese Vermutung wird durch Ergebnisse aus Rezeptorexpressions-Experimenten in mit der 118G Variante des µ-Opioidrezeptor-Gens transfizierten HEK 293-Zellen und CHO-Zellen untermauert. Im Gegensatz dazu gibt es auch Veröffentlichungen, in denen die Rezeptorexpression in mit der 118G Variante transfizierten HEK 293-Zellen und COS-Zellen unverändert war. Daher ist der endgültige Beweis, dass die µ-Opioidrezeptorexpression in Trägern der 118G Variante verringert ist, noch nicht erbracht. ...
- Published
- 2008
14. Linkage between increased nociception and olfaction via a SCN9A haplotype
- Author
-
Heimann, Dirk, Lötsch, Jörn, Hummel, Thomas, Doehring, Alexandra, Oertel, Bruno Georg, Heimann, Dirk, Lötsch, Jörn, Hummel, Thomas, Doehring, Alexandra, and Oertel, Bruno Georg
- Abstract
Background and Aims: Mutations reducing the function of Nav1.7 sodium channels entail diminished pain perception and olfactory acuity, suggesting a link between nociception and olfaction at ion channel level. We hypothesized that if such link exists, it should work in both directions and gain-of-function Nav1.7 mutations known to be associated with increased pain perception should also increase olfactory acuity. Methods: SCN9A variants were assessed known to enhance pain perception and found more frequently in the average population. Specifically, carriers of SCN9A variants rs41268673C>A (P610T; n = 14) or rs6746030C>T (R1150W; n = 21) were compared with non-carriers (n = 40). Olfactory function was quantified by assessing odor threshold, odor discrimination and odor identification using an established olfactory test. Nociception was assessed by measuring pain thresholds to experimental nociceptive stimuli (punctate and blunt mechanical pressure, heat and electrical stimuli). Results: The number of carried alleles of the non-mutated SCN9A haplotype rs41268673C/rs6746030C was significantly associated with the comparatively highest olfactory threshold (0 alleles: threshold at phenylethylethanol dilution step 12 of 16 (n = 1), 1 allele: 10.6±2.6 (n = 34), 2 alleles: 9.5±2.1 (n = 40)). The same SCN9A haplotype determined the pain threshold to blunt pressure stimuli (0 alleles: 21.1 N/m2, 1 allele: 29.8±10.4 N/m2, 2 alleles: 33.5±10.2 N/m2). Conclusions: The findings established a working link between nociception and olfaction via Nav1.7 in the gain-of-function direction. Hence, together with the known reduced olfaction and pain in loss-of-function mutations, a bidirectional genetic functional association between nociception and olfaction exists at Nav1.7 level.
- Published
- 2013
15. The human operculo-insular cortex is pain-preferentially but not pain-exclusively activated by trigeminal and olfactory stimuli
- Author
-
Lötsch, Jörn, Walter, Carmen, Felden, Lisa, Nöth, Ulrike, Deichmann, Ralf, Oertel, Bruno Georg, Lötsch, Jörn, Walter, Carmen, Felden, Lisa, Nöth, Ulrike, Deichmann, Ralf, and Oertel, Bruno Georg
- Abstract
Increasing evidence about the central nervous representation of pain in the brain suggests that the operculo-insular cortex is a crucial part of the pain matrix. The pain-specificity of a brain region may be tested by administering nociceptive stimuli while controlling for unspecific activations by administering non-nociceptive stimuli. We applied this paradigm to nasal chemosensation, delivering trigeminal or olfactory stimuli, to verify the pain-specificity of the operculo-insular cortex. In detail, brain activations due to intranasal stimulation induced by non-nociceptive olfactory stimuli of hydrogen sulfide (5 ppm) or vanillin (0.8 ppm) were used to mask brain activations due to somatosensory, clearly nociceptive trigeminal stimulations with gaseous carbon dioxide (75% v/v). Functional magnetic resonance (fMRI) images were recorded from 12 healthy volunteers in a 3T head scanner during stimulus administration using an event-related design. We found that significantly more activations following nociceptive than non-nociceptive stimuli were localized bilaterally in two restricted clusters in the brain containing the primary and secondary somatosensory areas and the insular cortices consistent with the operculo-insular cortex. However, these activations completely disappeared when eliminating activations associated with the administration of olfactory stimuli, which were small but measurable. While the present experiments verify that the operculo-insular cortex plays a role in the processing of nociceptive input, they also show that it is not a pain-exclusive brain region and allow, in the experimental context, for the interpretation that the operculo-insular cortex splay a major role in the detection of and responding to salient events, whether or not these events are nociceptive or painful.
- Published
- 2012
16. Quick discrimination of A delta and C fiber mediated pain based on three verbal descriptors
- Author
-
Beißner, Florian, Brandau, Amadeus, Henke, Christian, Felden, Lisa, Baumgärtner, Ulf, Treede, Rolf-Detlef, Oertel, Bruno Georg, Lötsch, Jörn, Beißner, Florian, Brandau, Amadeus, Henke, Christian, Felden, Lisa, Baumgärtner, Ulf, Treede, Rolf-Detlef, Oertel, Bruno Georg, and Lötsch, Jörn
- Abstract
Background: A delta and C fibers are the major pain-conducting nerve fibers, activate only partly the same brain areas, and are differently involved in pain syndromes. Whether a stimulus excites predominantly A delta or C fibers is a commonly asked question in basic pain research but a quick test was lacking so far. Methodology/Principal Findings: Of 77 verbal descriptors of pain sensations, "pricking", "dull" and "pressing" distinguished best (95% cases correctly) between A delta fiber mediated (punctate pressure produced by means of von Frey hairs) and C fiber mediated (blunt pressure) pain, applied to healthy volunteers in experiment 1. The sensation was assigned to A delta fibers when "pricking" but neither "dull" nor "pressing" were chosen, and to C fibers when the sum of the selections of "dull" or "pressing" was greater than that of the selection of "pricking". In experiment 2, with an independent cohort, the three-descriptor questionnaire achieved sensitivity and specificity above 0.95 for distinguishing fiber preferential non-mechanical induced pain (laser heat, exciting A delta fibers, and 5-Hz electric stimulation, exciting C fibers). Conclusion: A three-item verbal rating test using the words "pricking", "dull", and "pressing" may provide sufficient information to characterize a pain sensation evoked by a physical stimulus as transmitted via A delta or via C fibers. It meets the criteria of a screening test by being easy to administer, taking little time, being comfortable in handling, and inexpensive while providing high specificity for relevant information.
- Published
- 2010
17. Mu-opioid receptor gene variant OPRM1 118A>G : a genetic modulator of opioid effects
- Author
-
Oertel, Bruno Georg and Oertel, Bruno Georg
- Abstract
The µ-opioid receptor is the primary target structure of most opioid analgesics and thus responsible for the predominant part of their wanted and unwanted effects. Carriers of the frequent genetic µ-opioid receptor variant N40D (allelic frequency 8.2 - 17 %), coded by the single nucleotide polymorphism A>G at position 118 of the µ-opioid receptor coding gene OPRM1 (OPRM1 118A>G SNP), suffer from a decreased opioid potency and from a higher need of opioid analgesics to reach adequate analgesia. The aim of the present work was to identify the mechanism by which the OPRM1 118A>G SNP decreases the opioid potency and to quantify its effects on the analgesic potency and therapeutic range of opioid analgesics. To elucidate the consequences of the OPRM1 118A>G SNP for the effects of opioid analgesics, brain regions of healthy homozygous carriers of the OPRM1 118A>G SNP were identified by means of functional magnetic resonace imaging (fMRI), where the variant alters the response to opioid analgesics after painful stimulation. Afterwards, the µ-opioid receptor function was analyzed on a molecular level in post mortem samples of these brain regions. Finally, the consequences of the OPRM1 118A>G SNP for the analgesic and respiratory depressive effects of opioids were quantified in healthy carriers and non-carriers of OPRM1 118A>G SNP by means of experimental pain- and respiratory depression-models. To identify pain processing brain regions, where the variant alters the response to opioid analgesics after painful stimulation, we investigated the effects of different alfentanil concentration levels (0, 25, 50 and 75 ng/ml) on pain-related brain activation achieved by short pulses (300 msec) of gaseous CO2 (66% v/v) delivered to the nasal mucosa using a 3.0 T magnetic head scanner in 16 non-carriers and nine homozygous carriers of the µ-opioid receptor gene variant OPRM1 118A>G. In brain regions associated with the processing of the sensory dimension of pain (pain intensity), such, Opioidanalgetika sind bis heute das adäquate Mittel zur Behandlung schwerer Schmerzzustände. Dabei wird ihre breite Anwendbarkeit durch opioidtypische unerwünschte Nebenwirkungen wie Atemdepression, Benommenheit, Übelkeit bis zum Erbrechen, Obstipation, Miosis und juckende Hautreizung eingeschränkt. Das Ausmaß der auftretenden Opioidwirkungen variiert von Patient zu Patient. Fortschritte in der genetischen Forschung haben gezeigt, dass ein Teil der Variabilität von Opioidwirkungen in der genetischen Variabilität der Bevölkerung begründet liegt. Opioide wirken über G-Protein-gekoppelte Rezeptoren, die Opioidrezeptoren, bestehend aus dem μ-, κ-, δ-Opioidrezeptor. Anhand von μ-Opioidrezeptor-Knockout-Mäusen konnte gezeigt werden, dass vor allem die μ-Opioidrezeptoren für den überwiegenden Teil der erwünschten und unerwünschten Wirkungen von Opioidanalgetika verantwortlich sind. Die μ-Opioidrezeptoren werden vom OPRM1 Gen codiert. Bei einer häufigen genetischen Variante des μ- Opioidrezeptor-Gens OPRM1 (Allelfrequenz ca. 8,2-17%) steht an Position 118 in Exon 1 das Nukleotid Adenin anstatt Guanin (OPRM1-118A>G-Polymorphismus). Als Folge wird anstelle von Asparagin die Aminosäure Aspartat an Position 40 (N40D) der N-terminalen extrazellulä- ren Rezeptorbindungsdomäne eingebaut. Bei Trägern der μ-Opioidrezeptor-Variante N40D wurde wiederholt eine Verminderung der Opioidpotenz und ein erhöhter Bedarf von Opioidanalgetika zur adäquaten Schmerzstillung im Vergleich zu Nichtträgern der Variante beobachtet. Desweiteren weisen einige Studien auf eine Erhöhung der therapeutischen Breite von Opioidanalgetika in Trägern dieser Variante hin. So benötigten Träger der N40D Variante im Vergleich zu Nichtträgern höhere Konzentrationen von Alfentanil (1,3-fach) bzw. Morphin (2-fach), um die gleiche Analgesie bei postoperativen Schmerzen zu erreichen, und dennoch waren sie weniger von opioidtypischen unerwünschten Wirkungen betroffen. Die miotischen Effekte von Morphin, seines aktiven Me
- Published
- 2008
18. A Common Human μ-Opioid Receptor Genetic Variant Diminishes the Receptor Signaling Efficacy in Brain Regions Processing the Sensory Information of Pain
- Author
-
Oertel, Bruno Georg, primary, Kettner, Mattias, additional, Scholich, Klaus, additional, Renné, Christoph, additional, Roskam, Bianca, additional, Geisslinger, Gerd, additional, Schmidt, Peter Harald, additional, and Lötsch, Jörn, additional
- Published
- 2009
- Full Text
- View/download PDF
19. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain.
- Author
-
Oertel BG, Kettner M, Scholich K, Renné C, Roskam B, Geisslinger G, Schmidt PH, and Lötsch J
- Subjects
- Alleles, Analgesics, Opioid pharmacology, Asparagine genetics, Asparagine metabolism, Aspartic Acid genetics, Aspartic Acid metabolism, Enkephalin, Ala(2)-MePhe(4)-Gly(5)- pharmacology, Gene Expression Regulation drug effects, Gene Expression Regulation physiology, Homozygote, Humans, Pain genetics, Protein Structure, Tertiary, Receptors, Opioid, mu agonists, Receptors, Opioid, mu genetics, Amino Acid Substitution, Pain metabolism, Polymorphism, Single Nucleotide, Receptors, Opioid, mu metabolism, Somatosensory Cortex metabolism, Thalamus metabolism
- Abstract
The single nucleotide polymorphism 118A>G of the human micro-opioid receptor gene OPRM1, which leads to an exchange of the amino acid asparagine (N) to aspartic acid (D) at position 40 of the extracellular receptor region, alters the in vivo effects of opioids to different degrees in pain-processing brain regions. The most pronounced N40D effects were found in brain regions involved in the sensory processing of pain intensity. Using the mu-opioid receptor-specific agonist DAMGO, we analyzed the micro-opioid receptor signaling, expression, and binding affinity in human brain tissue sampled postmortem from the secondary somatosensory area (SII) and from the ventral posterior part of the lateral thalamus, two regions involved in the sensory processing and transmission of nociceptive information. We show that the main effect of the N40D micro-opioid receptor variant is a reduction of the agonist-induced receptor signaling efficacy. In the SII region of homo- and heterozygous carriers of the variant 118G allele (n=18), DAMGO was only 62% as efficient (p=0.002) as in homozygous carriers of the wild-type 118A allele (n=15). In contrast, the number of [3H]DAMGO binding sites was unaffected. Hence, the micro-opioid receptor G-protein coupling efficacy in SII of carriers of the 118G variant was only 58% as efficient as in homozygous carriers of the 118A allele (p<0.001). The thalamus was unaffected by the OPRM1 118A>G SNP. In conclusion, we provide a molecular basis for the reduced clinical effects of opioid analgesics in carriers of mu-opioid receptor variant N40D.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.